Connection

JAMES P ALLISON to Lymphocyte Activation

This is a "connection" page, showing publications JAMES P ALLISON has written about Lymphocyte Activation.
Connection Strength

4.391
  1. Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States. Immunity. 2019 04 16; 50(4):1084-1098.e10.
    View in: PubMed
    Score: 0.458
  2. Pillars article: CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. The journal of experimental medicine. 1995. 182: 459-465. J Immunol. 2011 Oct 01; 187(7):3459-65.
    View in: PubMed
    Score: 0.273
  3. Strength of TCR-peptide/MHC interactions and in vivo T cell responses. J Immunol. 2011 May 01; 186(9):5039-45.
    View in: PubMed
    Score: 0.265
  4. Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS). Curr Opin Immunol. 2010 Jun; 22(3):326-32.
    View in: PubMed
    Score: 0.243
  5. Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. Immunol Rev. 2009 May; 229(1):67-87.
    View in: PubMed
    Score: 0.231
  6. The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res. 2007 Sep 15; 13(18 Pt 1):5271-9.
    View in: PubMed
    Score: 0.206
  7. To be or not to be B7. J Clin Invest. 2006 Oct; 116(10):2590-3.
    View in: PubMed
    Score: 0.193
  8. MHC class II-independent and -dependent T cell expansion and B cell hyperactivity in vivo in mice deficient in CD152 (CTLA-4). Int Immunol. 2004 Jul; 16(7):895-904.
    View in: PubMed
    Score: 0.163
  9. B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci U S A. 2003 Sep 02; 100(18):10388-92.
    View in: PubMed
    Score: 0.155
  10. The lymphoproliferative defect in CTLA-4-deficient mice is ameliorated by an inhibitory NK cell receptor. Blood. 2002 Jun 15; 99(12):4509-16.
    View in: PubMed
    Score: 0.143
  11. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discov. 2018 09; 8(9):1069-1086.
    View in: PubMed
    Score: 0.110
  12. Co-stimulation in T cell responses. Curr Opin Immunol. 1997 Jun; 9(3):396-404.
    View in: PubMed
    Score: 0.101
  13. Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nat Commun. 2017 02 13; 8:14340.
    View in: PubMed
    Score: 0.099
  14. Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr Opin Immunol. 1995 Oct; 7(5):682-6.
    View in: PubMed
    Score: 0.090
  15. Checkpoints. Cell. 2015 Sep 10; 162(6):1202-5.
    View in: PubMed
    Score: 0.090
  16. T-cell activation: integration of signals from the antigen receptor and costimulatory molecules. Immunol Today. 1995 Jul; 16(7):306-10.
    View in: PubMed
    Score: 0.088
  17. The future of immune checkpoint therapy. Science. 2015 Apr 03; 348(6230):56-61.
    View in: PubMed
    Score: 0.087
  18. Friends not foes: CTLA-4 blockade and mTOR inhibition cooperate during CD8+ T cell priming to promote memory formation and metabolic readiness. J Immunol. 2015 Mar 01; 194(5):2089-98.
    View in: PubMed
    Score: 0.086
  19. CD28-B7 interactions in T-cell activation. Curr Opin Immunol. 1994 Jun; 6(3):414-9.
    View in: PubMed
    Score: 0.082
  20. Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res. 2013 Oct; 1(4):229-34.
    View in: PubMed
    Score: 0.077
  21. Cutting edge: CTLA-4 on effector T cells inhibits in trans. J Immunol. 2012 Aug 01; 189(3):1123-7.
    View in: PubMed
    Score: 0.072
  22. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature. 1992 Apr 16; 356(6370):607-9.
    View in: PubMed
    Score: 0.071
  23. Attenuated T cell responses to a high-potency ligand in vivo. PLoS Biol. 2010 Sep 14; 8(9).
    View in: PubMed
    Score: 0.063
  24. TCR ligand density and affinity determine peripheral induction of Foxp3 in vivo. J Exp Med. 2010 Aug 02; 207(8):1701-11.
    View in: PubMed
    Score: 0.063
  25. Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol. 2009 Jul; 157(1):9-19.
    View in: PubMed
    Score: 0.057
  26. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood. 2008 Aug 15; 112(4):1175-83.
    View in: PubMed
    Score: 0.054
  27. A genetic library screen for signaling proteins that interact with phosphorylated T cell costimulatory receptors. Genomics. 2006 Dec; 88(6):841-845.
    View in: PubMed
    Score: 0.048
  28. CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism. J Immunol. 2006 Jul 15; 177(2):1052-61.
    View in: PubMed
    Score: 0.048
  29. Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells. J Immunol. 2005 Feb 15; 174(4):1922-31.
    View in: PubMed
    Score: 0.043
  30. B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity. 2004 Sep; 21(3):401-13.
    View in: PubMed
    Score: 0.042
  31. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol. 2003 Jul; 4(7):670-9.
    View in: PubMed
    Score: 0.038
  32. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol. 2002 Jul; 3(7):611-8.
    View in: PubMed
    Score: 0.036
  33. Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity. 2002 Jan; 16(1):23-35.
    View in: PubMed
    Score: 0.035
  34. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer. J Immunother Cancer. 2021 05; 9(5).
    View in: PubMed
    Score: 0.033
  35. Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nat Commun. 2020 01 30; 11(1):603.
    View in: PubMed
    Score: 0.030
  36. Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients? Am Soc Clin Oncol Educ Book. 2019 Jan; 39:147-164.
    View in: PubMed
    Score: 0.029
  37. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci U S A. 2019 01 29; 116(5):1692-1697.
    View in: PubMed
    Score: 0.028
  38. Itk negatively regulates induction of T cell proliferation by CD28 costimulation. J Exp Med. 1997 Jul 21; 186(2):221-8.
    View in: PubMed
    Score: 0.026
  39. Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor Immunity. J Immunol. 2017 08 01; 199(3):974-981.
    View in: PubMed
    Score: 0.025
  40. T cell-mediated elimination of B7.2 transgenic B cells. Immunity. 1997 Mar; 6(3):327-39.
    View in: PubMed
    Score: 0.025
  41. Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade. Cancer Immunol Res. 2017 02; 5(2):100-105.
    View in: PubMed
    Score: 0.025
  42. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016 08 30; 7:12632.
    View in: PubMed
    Score: 0.024
  43. ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40-Mediated Tumor Rejection. Cancer Res. 2016 07 01; 76(13):3684-9.
    View in: PubMed
    Score: 0.023
  44. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy. 2015; 7(9):967-980.
    View in: PubMed
    Score: 0.022
  45. Co-stimulation via CD28 induces activation of a refractory subset of MRL-lpr/lpr T lymphocytes. Int Immunol. 1993 Nov; 5(11):1451-60.
    View in: PubMed
    Score: 0.020
  46. Activation and differentiation requirements of primary T cells in vitro. Proc Natl Acad Sci U S A. 1993 Oct 01; 90(19):8987-91.
    View in: PubMed
    Score: 0.020
  47. Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients. Cancer Immunol Res. 2013 Oct; 1(4):235-44.
    View in: PubMed
    Score: 0.020
  48. CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help. J Exp Med. 1993 Jun 01; 177(6):1791-6.
    View in: PubMed
    Score: 0.019
  49. T cell receptor-triggered activation of intraepithelial lymphocytes in vitro. Int Immunol. 1993 Feb; 5(2):145-53.
    View in: PubMed
    Score: 0.019
  50. Augmented IL-15Ra expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice. J Immunol. 2012 Jun 15; 188(12):6156-64.
    View in: PubMed
    Score: 0.018
  51. CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases. Cancer Immunol Immunother. 2011 Aug; 60(8):1137-46.
    View in: PubMed
    Score: 0.016
  52. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Clin Cancer Res. 2010 May 15; 16(10):2781-91.
    View in: PubMed
    Score: 0.015
  53. Structure, function, and serology of the T-cell antigen receptor complex. Annu Rev Immunol. 1987; 5:503-40.
    View in: PubMed
    Score: 0.012
  54. B7 expression on T cells down-regulates immune responses through CTLA-4 ligation via T-T interactions [corrections]. J Immunol. 2004 Jan 01; 172(1):34-9.
    View in: PubMed
    Score: 0.010
  55. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003 Jul 08; 100(14):8372-7.
    View in: PubMed
    Score: 0.010
  56. Cutting edge: a crucial role for B7-CD28 in transmitting T help from APC to CTL. J Immunol. 2002 Oct 15; 169(8):4094-7.
    View in: PubMed
    Score: 0.009
  57. Human DR (Ia-like) antigens: biological and molecular profile. Contemp Top Mol Immunol. 1978; 7:239-81.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.